Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER: Brilaroxazine in Schizophrenia
NCT05184335Phase 3Recruiting
- Sponsor
- Reviva Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brilaroxazine in schizophrenia (3 arms), sponsored by Reviva Pharmaceuticals. Primary endpoints: Positive and Negative Syndrome Scale Total Score Change from Baseline at 28 days and Open Label Safety and Efficacy of Brilaroxazine at 52 weeks. Started Jan 2022; status: recruiting.
02
Drugs
brilaroxazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05184335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184335.